Article 1) As we already know, Enzalutamide and Abiraterone are both major breakthroughs in prostate cancer. The combination of Enzalutamide plus Abiraterone acetate may lead to more profound suppression of androgen signaling than with either agent alone!
Article 2) Here is a current list of new and upcoming clinical trials for PCa. All new and potential PCa breakthroughs come exclusively from clinical trials before FDA grants approval for release. This sight offers 1777 clinical trials around the world. Many are here in the U.S. Most of the new PCa breakthroughs should come from this pool of trials.
#1) Enzalutamide Plus Abiraterone May Have Higher Response Rate
“These findings confirm the hypothesis that co-targeting mCRPC with enzalutamide and abiraterone acetate avoids the adaptive response observed with either agent alone and suggest that the combination may have a more profound response rate than either agent alone and that it is well tolerated,” the researchers concluded. Discussant Gerhardt Attard, MD, PhD, Cancer Research UK Clinical Scientist, Royal Marsden NHS Foundation Trust, UK, agreed with MD Anderson investigators that their study confirms the tolerability of the combination”.
#2) PCa Cancer Clinical Trial Search! This list shows all 1777 clinical trials for Prostate cancer. Worth looking through.
Remember, Lost time can never be found!
The New Denver Men’s Club
“Men Fighting Cancer To Win”